Cargando…

6% Hydroxyethyl starch (HES 130/0.4) diminishes glycocalyx degradation and decreases vascular permeability during systemic and pulmonary inflammation in mice

BACKGROUND: Increased vascular permeability is a pathophysiological hallmark of sepsis and results in increased transcapillary leakage of plasma fluid, hypovolemia, and interstitial edema formation. 6% hydroxyethyl starch (HES 130/0.4) is commonly used to treat hypovolemia to maintain adequate organ...

Descripción completa

Detalles Bibliográficos
Autores principales: Margraf, Andreas, Herter, Jan M., Kühne, Katharina, Stadtmann, Anika, Ermert, Thomas, Wenk, Manuel, Meersch, Melanie, Van Aken, Hugo, Zarbock, Alexander, Rossaint, Jan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5930811/
https://www.ncbi.nlm.nih.gov/pubmed/29716625
http://dx.doi.org/10.1186/s13054-017-1846-3
_version_ 1783319543659102208
author Margraf, Andreas
Herter, Jan M.
Kühne, Katharina
Stadtmann, Anika
Ermert, Thomas
Wenk, Manuel
Meersch, Melanie
Van Aken, Hugo
Zarbock, Alexander
Rossaint, Jan
author_facet Margraf, Andreas
Herter, Jan M.
Kühne, Katharina
Stadtmann, Anika
Ermert, Thomas
Wenk, Manuel
Meersch, Melanie
Van Aken, Hugo
Zarbock, Alexander
Rossaint, Jan
author_sort Margraf, Andreas
collection PubMed
description BACKGROUND: Increased vascular permeability is a pathophysiological hallmark of sepsis and results in increased transcapillary leakage of plasma fluid, hypovolemia, and interstitial edema formation. 6% hydroxyethyl starch (HES 130/0.4) is commonly used to treat hypovolemia to maintain adequate organ perfusion and oxygen delivery. The present study was designed to investigate the effects of 6% HES 130/0.4 on glycocalyx integrity and vascular permeability in lipopolysaccharide (LPS)-induced pulmonary inflammation and systemic inflammation in mice. METHODS: 6% HES 130/0.4 or a balanced electrolyte solution (20 ml/kg) was administered intravenously 1 h after cecal ligation and puncture (CLP) or LPS inhalation. Sham-treated animals receiving 6% HES 130/0.4 or the electrolyte solution served as controls. The thickness of the endovascular glycocalyx was visualized by intravital microscopy in lung (LPS inhalation model) or cremaster muscle (CLP model). Syndecan-1, hyaluronic acid, and heparanase levels were measured in blood samples. Vascular permeability in the lungs, liver, kidney, and brain was measured by Evans blue extravasation. RESULTS: Both CLP induction and LPS inhalation resulted in increased vascular permeability in the lung, liver, kidney, and brain. 6% HES 130/0.4 infusion led to significantly reduced plasma levels of syndecan-1, heparanase, and hyaluronic acid, which was accompanied by a preservation of the glycocalyx thickness in postcapillary venules of the cremaster (0.78 ± 0.09 μm vs. 1.39 ± 0.10 μm) and lung capillaries (0.81 ± 0.09 μm vs. 1.49 ± 0.12 μm). CONCLUSIONS: These data suggest that 6% HES 130/0.4 exerts protective effects on glycocalyx integrity and attenuates the increase of vascular permeability during systemic inflammation. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi: 10.1186/s13054-017-1846-3) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5930811
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-59308112018-05-09 6% Hydroxyethyl starch (HES 130/0.4) diminishes glycocalyx degradation and decreases vascular permeability during systemic and pulmonary inflammation in mice Margraf, Andreas Herter, Jan M. Kühne, Katharina Stadtmann, Anika Ermert, Thomas Wenk, Manuel Meersch, Melanie Van Aken, Hugo Zarbock, Alexander Rossaint, Jan Crit Care Research BACKGROUND: Increased vascular permeability is a pathophysiological hallmark of sepsis and results in increased transcapillary leakage of plasma fluid, hypovolemia, and interstitial edema formation. 6% hydroxyethyl starch (HES 130/0.4) is commonly used to treat hypovolemia to maintain adequate organ perfusion and oxygen delivery. The present study was designed to investigate the effects of 6% HES 130/0.4 on glycocalyx integrity and vascular permeability in lipopolysaccharide (LPS)-induced pulmonary inflammation and systemic inflammation in mice. METHODS: 6% HES 130/0.4 or a balanced electrolyte solution (20 ml/kg) was administered intravenously 1 h after cecal ligation and puncture (CLP) or LPS inhalation. Sham-treated animals receiving 6% HES 130/0.4 or the electrolyte solution served as controls. The thickness of the endovascular glycocalyx was visualized by intravital microscopy in lung (LPS inhalation model) or cremaster muscle (CLP model). Syndecan-1, hyaluronic acid, and heparanase levels were measured in blood samples. Vascular permeability in the lungs, liver, kidney, and brain was measured by Evans blue extravasation. RESULTS: Both CLP induction and LPS inhalation resulted in increased vascular permeability in the lung, liver, kidney, and brain. 6% HES 130/0.4 infusion led to significantly reduced plasma levels of syndecan-1, heparanase, and hyaluronic acid, which was accompanied by a preservation of the glycocalyx thickness in postcapillary venules of the cremaster (0.78 ± 0.09 μm vs. 1.39 ± 0.10 μm) and lung capillaries (0.81 ± 0.09 μm vs. 1.49 ± 0.12 μm). CONCLUSIONS: These data suggest that 6% HES 130/0.4 exerts protective effects on glycocalyx integrity and attenuates the increase of vascular permeability during systemic inflammation. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi: 10.1186/s13054-017-1846-3) contains supplementary material, which is available to authorized users. BioMed Central 2018-05-01 /pmc/articles/PMC5930811/ /pubmed/29716625 http://dx.doi.org/10.1186/s13054-017-1846-3 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Margraf, Andreas
Herter, Jan M.
Kühne, Katharina
Stadtmann, Anika
Ermert, Thomas
Wenk, Manuel
Meersch, Melanie
Van Aken, Hugo
Zarbock, Alexander
Rossaint, Jan
6% Hydroxyethyl starch (HES 130/0.4) diminishes glycocalyx degradation and decreases vascular permeability during systemic and pulmonary inflammation in mice
title 6% Hydroxyethyl starch (HES 130/0.4) diminishes glycocalyx degradation and decreases vascular permeability during systemic and pulmonary inflammation in mice
title_full 6% Hydroxyethyl starch (HES 130/0.4) diminishes glycocalyx degradation and decreases vascular permeability during systemic and pulmonary inflammation in mice
title_fullStr 6% Hydroxyethyl starch (HES 130/0.4) diminishes glycocalyx degradation and decreases vascular permeability during systemic and pulmonary inflammation in mice
title_full_unstemmed 6% Hydroxyethyl starch (HES 130/0.4) diminishes glycocalyx degradation and decreases vascular permeability during systemic and pulmonary inflammation in mice
title_short 6% Hydroxyethyl starch (HES 130/0.4) diminishes glycocalyx degradation and decreases vascular permeability during systemic and pulmonary inflammation in mice
title_sort 6% hydroxyethyl starch (hes 130/0.4) diminishes glycocalyx degradation and decreases vascular permeability during systemic and pulmonary inflammation in mice
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5930811/
https://www.ncbi.nlm.nih.gov/pubmed/29716625
http://dx.doi.org/10.1186/s13054-017-1846-3
work_keys_str_mv AT margrafandreas 6hydroxyethylstarchhes13004diminishesglycocalyxdegradationanddecreasesvascularpermeabilityduringsystemicandpulmonaryinflammationinmice
AT herterjanm 6hydroxyethylstarchhes13004diminishesglycocalyxdegradationanddecreasesvascularpermeabilityduringsystemicandpulmonaryinflammationinmice
AT kuhnekatharina 6hydroxyethylstarchhes13004diminishesglycocalyxdegradationanddecreasesvascularpermeabilityduringsystemicandpulmonaryinflammationinmice
AT stadtmannanika 6hydroxyethylstarchhes13004diminishesglycocalyxdegradationanddecreasesvascularpermeabilityduringsystemicandpulmonaryinflammationinmice
AT ermertthomas 6hydroxyethylstarchhes13004diminishesglycocalyxdegradationanddecreasesvascularpermeabilityduringsystemicandpulmonaryinflammationinmice
AT wenkmanuel 6hydroxyethylstarchhes13004diminishesglycocalyxdegradationanddecreasesvascularpermeabilityduringsystemicandpulmonaryinflammationinmice
AT meerschmelanie 6hydroxyethylstarchhes13004diminishesglycocalyxdegradationanddecreasesvascularpermeabilityduringsystemicandpulmonaryinflammationinmice
AT vanakenhugo 6hydroxyethylstarchhes13004diminishesglycocalyxdegradationanddecreasesvascularpermeabilityduringsystemicandpulmonaryinflammationinmice
AT zarbockalexander 6hydroxyethylstarchhes13004diminishesglycocalyxdegradationanddecreasesvascularpermeabilityduringsystemicandpulmonaryinflammationinmice
AT rossaintjan 6hydroxyethylstarchhes13004diminishesglycocalyxdegradationanddecreasesvascularpermeabilityduringsystemicandpulmonaryinflammationinmice